Mei, Yihan
Liu, Yu
Liu, Wenbing
Chen, Manling
Liu, Xiaoyu
Wang, Shangshang
Mou, Junli
Xing, Haiyan
Tang, Kejing
Tian, Zheng
Rao, Qing
Wang, Min
Gu, Runxia
Qiu, Shaowei
Wang, Jianxiang
Funding for this research was provided by:
National Key Research and Development Program of China (2021YFC2500300)
CAMS Innovation Fund for Medical Sciences (2021-I2M-1-041)
National Natural Science Foundation of China (82000131)
Clinical Research Foundation of National Clinical Research Center for Blood Diseases (2023NCRCA0101)
Tianjin Municipal Science and Technology Commission Grant (23JCYBJC01050)
Article History
Received: 26 June 2024
Accepted: 31 August 2024
First Online: 6 September 2024
Declarations
:
: This research was approved by the ethical committee in the Institute of Hematology and Blood Diseases Hospital, and all procedures were in accordance with the Helsinki Declaration. Written informed consent was obtained from each participant. All mouse-related experimental procedures underwent review and approval by the ethics committee.
: All authors approved the contents of the manuscript and agreed to the submission and publication for <i>Experimental Hematology & Oncology</i>.
: JW: Advisor for AbbVie. Other authors declare no competing interests.